復星醫藥(02196.HK)及復星國際(00656.HK)：Gland Pharma在印度遞交非正式招股書草稿
格隆匯 7 月 10日丨復星醫藥(02196.HK)及復星國際(00656.HK)聯合宣佈，復星醫藥及復星國際已根據第15項應用指引向香港聯交所聯合申請批准建議分拆及獨立上市，而香港聯交所已確認復星醫藥及復星國際可進行建議分拆及獨立上市。
復星醫藥及復星國際接獲通知，Gland Pharma(i)已於2020年7月10日就建議首次公開發售其股份向SEBI、印度證交所及孟買證交所遞交非正式招股書草稿；並(ii)將就其股份在印度證交所及孟買證交所上市申請原則性批准。
預計建議分拆及獨立上市將涉及Gland Pharma以首次公開發售的方式發行總額不超過125億盧比的新股份，以及由Gland Pharma現有股東售出的不超過3486.36萬股股份。具體發行規模(包括超額認購)將根據SEBIICDR規例及適用的SEBI指引、規則、規例及通知最終確定。於建議分拆及獨立上市後，Gland Pharma將仍為復星醫藥及復星國際的附屬公司。
建議分拆及獨立上市有利於復星國際及復星醫藥的業務發展，並將為Gland Pharma提供獨立的融資平台。
建議分拆及獨立上市將復星國際及復星醫藥的業務與Gland Pharma的業務實質性地分離，可讓投資者及金融業界分別評估復星國際、復星醫藥及Gland Pharma業務的戰略、成功要素、職能情況、風險及回報，並相應作出或改善其投資決策。建議分拆及獨立上市將使復星國際、復星醫藥及Gland Pharma的管理團隊更有效地專注於各自劃分明確的業務。此外，建議分拆及獨立上市將增加經營及財務透明度並提升企業管治水平，從而得以向投資者、金融機構及評級機構呈現Gland Pharma、復星國際及復星醫藥各自更為清晰的業務及財務狀況，這將使投資者對基於Gland Pharma、復星國際及復星醫藥表現、管理、策略、風險及回報的評估作出的投資決策更有信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
